Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M.
Solomon SR, et al. Among authors: vasu s.
Blood Adv. 2019 Oct 8;3(19):2836-2844. doi: 10.1182/bloodadvances.2019000627.
Blood Adv. 2019.
PMID: 31582392
Free PMC article.